enquiry@pharmascroll.com
Mail Us
-
FDA Approves Perseris (risperidone) for Schizophrenia treatment in Adults
- August 6, 2018
- Posted by: Pharmascroll
No CommentsIndivior announced that on July 27, 2018 the U.S. Food and Drug Administration (FDA) approved PERSERIS, the first once-monthly subcutaneous risperidone-containing, long-acting injectable (LAI) for the treatment of schizophrenia in adults. Clinically relevant levels were reached after the first injection of PERSERIS without use of a loading dose or any supplemental oral risperidone. “Treatment adherence
-
FDA Approves new Initiation drug, ARISTADA INITIO, for Schizophrenia
- July 3, 2018
- Posted by: Pharmascroll
Alkermes announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO™ (aripiprazole lauroxil) for the initiation of ARISTADA® (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. For the first time, ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, provides physicians with
-
Rxulti (brexpiprazole) for Schizophrenia gets positive CHMP opinion by EMA
- June 3, 2018
- Posted by: Pharmascroll
On 31 May 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rxulti, intended for the treatment of schizophrenia. Rxulti will be available as film-coated tablets (0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg).
-
Recent study identified Brain cells underlying Schizophrenia
- May 23, 2018
- Posted by: Pharmascroll
In the past, with few exceptions, the marked advances in knowledge about the genetic basis of schizophrenia have not converged on findings that can be confidently used for precise experimental modeling. A recent study, however, published in Nature Genetics, has evaluated, by applying knowledge of the cellular taxonomy of the brain from single-cell RNA sequencing,
-
Alkermes to Present Clinical Data related to Schizophrenia and Depression at American Psychiatric Association Annual Meeting
- May 2, 2018
- Posted by: Pharmascroll
Alkermes plc (Nasdaq: ALKS) announced the presentation of six posters highlighting data from the company’s schizophrenia and depression portfolios at the 2018 American Psychiatric Association (APA) Annual Meeting in New York, May 5-9, 2018. “Alkermes is pleased to present this important research as a continuation of our commitment to developing novel medicines in areas of
-
Schizophrenia drug ALKS 3831 completes Patient enrollment in a pivotal study
- April 27, 2018
- Posted by: Pharmascroll
Alkermes plc (Nasdaq: ALKS) announced completion of patient enrollment in ENLIGHTEN-2, the second of two key phase 3 studies in the ENLIGHTEN clinical development program for ALKS 3831, an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of schizophrenia. The multicenter, randomized, double-blind phase 3 study will evaluate the weight gain profile